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Many studies have chronicled the ‘‘epidemiologic synergy’’ between human immunodeficiency virus (HIV) and
herpes simplex virus type 2 (HSV-2). HIV adversely affects the natural history of HSV-2 and results in more
frequent and severe HSV-2 reactivation. Few longitudinal studies, however, have examined whether HSV-2 is
associated with increased HIV plasma viral loads or decreased CD4 counts. The authors estimated the effect of
HSV-2 seropositivity on HIV RNA viral load and on CD4 count over time among 777 HIV-seropositive US women
not receiving suppressive HSV-2 therapy in the HIV Epidemiology Research Study (1993–2000). Linear mixed
models were used to assess the effect of HSV-2 on log HIV viral load and CD4 count/mm3 prior to widespread
initiation of highly active antiretroviral therapy. Coinfection with HSV-2 was not associated with HIV RNA plasma
viral loads during study follow-up. There was a statistically significant association between HSV-2 seropositivity
and CD4 count over time, but this difference was small and counterintuitive at an increase of 8 cells/mm3 (95%
confidence interval: 2, 14) per year among HSV-2-seropositive women compared with HSV-2-seronegative
women. These data do not support a clinically meaningful effect of baseline HSV-2 seropositivity on the trajectories
of HIV plasma viral loads or CD4 counts.
CD4 lymphocyte count; herpes simplex; herpesvirus 2, human; HIV; viral load
Abbreviations: AIDS, acquired immunodeficiency syndrome; HAART, highly active antiretroviral therapy; HERS, HIV Epidemiol-
ogy Research Study; HIV, human immunodeficiency virus; HSV-2, herpes simplex virus type 2.
Many studies have chronicled the ‘‘epidemiologic syn-
ergy’’ between human immunodeficiency virus (HIV) and
herpes simplex virus type 2 (HSV-2) infections (1–3).
Chronic perianal ulceration due to HSV-2 infection was
one of the first opportunistic infections identified among
acquired immunodeficiency syndrome (AIDS) patients (4).
HSV-2 is one of the most common coinfections in HIV-
positive individuals, and more serious clinical manifesta-
tions of HSV-2 occur in those coinfected with HIV (5–7).
Reactivation of HSV-2 genital lesions is also more frequent
among women with HSV-2/HIV coinfections (8).
Few studies have examined the effect of HSV-2 on the
progression of HIV infection (8). A cross-sectional study of
men and women in Rakai, Uganda, found that HSV-2 sero-
positivity was associated with increased HIV viral load in
those with early HIV infection, but not in those with prev-
alent HIV infection (9). A second observational study in
Uganda found that individuals with prevalent HIV infection
coinfected with HSV-2 had viral loads 0.3-log-copies/mL
higher than those without HSV-2 infection (10). This finding
led to speculation that HSV-2 infection may affect the set
point of HIV viral load, leading to accelerated disease pro-
gression following initial HIV acquisition (8). Other coin-
fections in HIV-positive populations, such as tuberculosis
and hepatitis, have been associated with a more rapid de-
cline in CD4þ T cells and accelerated time to AIDS (11,
12). In addition, other herpesviruses have been associated
with AIDS-defining illnesses. Human herpesvirus 8, the
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etiologic agent of Kaposi’s sarcoma, stimulates HIV repli-
cation in acutely infected cells as well as reactivation in
chronically infected cells (13). If HSV-2 is shown to be
associated with higher HIV viral loads and a more rapid
decline in CD4 counts in HIV-positive individuals, screen-
ing HIV-positive individuals for HSV-2 seropositivity and
treating HSV/HIV-coinfected individuals with daily HSV-2
suppressive therapy may be warranted in addition to high-
ly active antiretroviral therapy (HAART) to slow HIV
progression.
Following the initial hypothesis that HSV-2 may affect
HIV progression, 2 subsequent longitudinal studies among
US men with early HIV infection found no association be-
tween HSV-2 seropositivity and HIV viral load (14, 15).
Data on the effect of HSV-2 seropositivity on HIV viral load
in HIV-infected individuals are therefore inconclusive and
are limited in women. Few data exist on the effect of HSV-2
seropositivity on CD4 count. In this study, we investigated
the associations of HSV-2 seropositivity with HIV plasma
viral load and CD4þ T-lymphocyte count over time among




The HERS study followed a cohort of women over a pe-
riod of 7 years (1993–2000) to examine the biologic, psy-
chological, and social effects of HIV infection on women’s
health. The study enrolled 871 HIV-infected and 439 HIV-
uninfected women aged 16–55 years from 4 cities (Balti-
more, Maryland; Bronx, New York; Detroit, Michigan; and
Providence, Rhode Island). The study rationale, organiza-
tion, and methods have been described in detail elsewhere
(16).
Only women who were HIV-positive at baseline (n ¼
871), had baseline HSV-2 results (25 women excluded),
and had at least 2 study visits (69 women excluded) were
included in the analyses, leaving a total of 777 women. To
address confounding by indication for HAART use, data
were right censored at January 1, 1998, before HAART
use was widespread in the HERS study (n ¼ 2,125 visits
excluded). Visits where women reported current use of acy-
clovir or valacyclovir (n ¼ 51 visits) were also excluded
from the analysis. These exclusions left 5,346 visits
(71.1% of the total visits) for analysis, with up to 10 possible
study visits per woman (each at approximately 6-month
intervals).
Laboratory methods
Antibodies to HIV were identified by enzyme-linked
immunosorbent assay and were confirmed by Western blot
using procedures standardized across study sites (16). Hep-
arinized whole blood was stained with monoclonal anti-
bodies using a modified whole blood method, and
percentages of CD4 T cells and CD4 counts were deter-
mined by flow cytometry and were calculated from com-
plete blood counts with differential, respectively (17).
Plasma HIV viral load was measured by the branched
DNA (bDNA) technique with lower limits of detection of
500 and 50 copies/mL (Chiron Corporation, Emeryville,
California). Date of immunologic AIDS diagnosis was de-
fined as the visit date on which a participant first had a CD4
count less than 200 or a CD4 percentage less than 14. Date
of clinical AIDS diagnosis was defined as the date on which
one or more of the AIDS-defining conditions included in the
1987 Centers for Disease Control and Prevention definition
were present on a participant’s medical record abstraction
form (18).
Sera obtained at baseline were tested for HSV-2 type-
specific antibodies using the reference standard Western blot
at the University of Washington. Laboratory measures for
the detection of syphilis, gonorrhea, Chlamydia trachoma-
tis, Trichomonas vaginalis, and Candida are described in
detail elsewhere (16).
Baseline statistical analyses
Associations between HSV-2 serostatus and baseline
characteristics were calculated using the Wilcoxon rank
sum test and the v2 statistic. For categorical variables with
any expected cell size less than 10, Fisher’s exact test was
used.
HIV RNA viral load was log10-transformed and measured
in log10 copies per milliliter, whereas CD4 T cells were
quantified as the number of cells per cubic millimeter of
blood divided by 100. HIV viral load values below the de-
tection limits of 500 or 50 copies/mL were assigned the
midpoint value of 250 or 25 copies/mL, respectively.
Mixed models
Separate linear mixed models were used to evaluate as-
sociations between the main exposure, HSV-2 serostatus at
baseline, and 1) HIV RNA viral load and 2) CD4 count over
time. Covariates considered for inclusion in both models
were time since baseline, the interaction between time and
HSV-2 serostatus, presence of other genital infections at
baseline, race, and age at baseline. Including an interaction
term between HSV-2 and time allowed estimation of the
effect of HSV-2 at baseline on change in viral load or
CD4. This was the main variable of interest. Presence of
other genital infections was coded as a dichotomous vari-
able and was used as a surrogate for genital immune reac-
tivity; women with T. vaginalis, Candida, chlamydia,
syphilis, or gonorrhea in the 6 months prior to the baseline
visit received a value of 1, whereas women without any of
these genital infections received a 0. Race was coded as
a dichotomous variable indicating whether or not a woman
was black or nonblack.
For the model with viral load as the outcome, CD4 count
at baseline was included as a covariate; similarly, for the
model with CD4 count as the outcome, viral load at baseline
was included as a covariate. All continuous variables (base-
line age, baseline CD4 count, and baseline viral load) were
centered at the median. To allow nonlinear relations with the
outcome, cubic splines with 4 knots at the 5th, 35th, 65th,
and 95th percentiles were fit for the continuous variables
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age, CD4 count, and viral load. The splines were restricted
to be linear beyond the outer knots, and nonlinear terms
were normalized by dividing by the square of the difference
in the outer knots (19). Nonlinear relations were explored by
including quadratic terms for time and the interaction be-
tween time and HSV-2. Interaction terms were retained in
the model if the likelihood ratio test comparing the model
without the interaction term with the full model was statis-
tically significant at an alpha level of 0.05. Potential con-
founders were retained in the model if removing them
changed the HSV-2 coefficient estimate by 10% or more
(20).
A mixed model was first fit with random intercepts for
each subject, and then models were fit by adding random
effects for slopes. The random effect for slopes did not
improve the fit of the model, and only random intercepts
were used in subsequent models. Model fit was evaluated
using likelihood ratio test statistics and by examining the
percentage of variation not explained by the random effects
included in the model. The effect of HSV-2 was evaluated
by examining the coefficients for HSV-2 and interaction
terms with time and the polynomial term for time.
Sensitivity analyses
To examine the effect of antiretroviral use that remained
after censoring the data at January 1, 1998, we performed
a sensitivity analysis in which we restricted the mixed
models to those person-visits where participants reported
no current use of antiretrovirals. We also performed a sensi-
tivity analysis in which we removed all visits where women
reported current use of the antiviral medications Cytovene
(Roche Pharmaceuticals, Nutley, New Jersey), Foscavir
(Astra Merck, Inc., Wayne, Pennsylvania), or amantadine
because these medications have suppressive effects on
HSV-2.
Proportional hazards model
The association between HSV-2 and time to clinical or
immunologic AIDS diagnosis was evaluated among HIV-
positive women at baseline using Cox proportional hazards
models. The models were adjusted for CD4 count at base-
line, presence of other genital infections in the 6 months
prior to baseline, race, and age at baseline centered at the
median of 35 years. Again, the data were censored at Janu-
ary 1, 1998, to examine the study period before HAART use
was widespread. The proportional hazards assumption was
evaluated by including interactions with categorical and
continuous time variables.
The analyses reported in this paper were generated using
SAS software, version 9.2 (SAS Institute, Inc., Cary, North
Carolina).
RESULTS
The median age of the 777 HIV-positive eligible women
was 35 years. Black, non-Hispanic was the largest racial
group (61.5%), followed by white, non-Hispanic (20.2%)
and Hispanic/Latino (18.3%). Most women were single
(43.0%), with a median reported age at first intercourse of
15 years. Among those women sexually active at baseline,
almost half (46.6%) reported that they did not always use
a condom in the 6 months prior to the baseline visit. HSV-2-
positive women were more likely to be black, non-Hispanic
(P¼ 0.0003) and were more likely to be older (P¼ 0.0009),
although the difference in median age between HSV-2-
positive and HSV-2-negative women was small (Table 1).
Approximately two-thirds of the women (67.8%) were
seropositive for HSV-2 at baseline. Almost three-quarters
of the women (74.1%) were seropositive for HSV-1 at base-
line, 38% of the women were culture-positive for Candida
(38.0%), and almost 13% were positive for T. vaginalis.
Prevalences of chlamydia (1.2%) and gonorrhea (0.5%)
were relatively low at baseline. Prevalence of syphilis was
higher, at 7.7%. HSV-1-seronegative women were more
likely to be HSV-2 seropositive, as were women with syph-
ilis. Among HSV-2-seronegative women, the prevalence of
hepatitis C virus was 60.4%, while the prevalence of hepa-
titis C virus among HSV-2-seropositive women was 60.8%.
Since hepatitis C virus positivity was not associated with
HSV-2 serostatus, it was not considered a confounder in the
mixed models.
The median baseline HIV viral load was similar between
HSV-2-seropositive (3.1 log copies/mL, 95% confidence in-
terval: 1.4, 5.7) and HSV-2-seronegative (3.2 log copies/mL,
95% confidence interval: 1.4, 5.3) women (P ¼ 0.44) (Table
1). Baseline CD4 count was slightly higher (P ¼ 0.06) for
those who were HSV-2 seronegative at baseline (median
CD4 count 412 cells/mm3 compared with 362 cells/mm3
for HSV-2-seropositive women) (Table 1).
After censoring, women completed between 2 and 10
study visits, with a median of 7. There were 278 visits
(5.2%) where a woman was currently receiving HAART
after censoring. Women were not using any antiretrovirals
at 3,074 visits (57.5%) and were on sub-HAART regimens
at 1,992 visits (37.3%). Data on HAART use were missing
for 2 women at one visit. There were 193 visits (3.6%) for
which a value for viral load was missing and 175 visits
(3.3%) for which a CD4 count was missing.
The final HIV viral load model was adjusted for baseline
CD4 count and its associated spline terms, presence of gen-
ital infections, and race (Table 2). Age was not retained in
the final model since removing it changed the HSV-2 co-
efficient estimate by less than 10%. The HSV-2 coefficient
and the coefficients representing the interaction between
HSV-2 and time were nonsignificant in the viral load model.
We also assessed whether the effect of HSV-2 on viral load
over time was nonlinear by including an interaction term
between HSV and the polynomial term for time. The likeli-
hood ratio test comparing the model without the interaction
term with the model with it was nonsignificant (P ¼ 0.10),
so the term was not retained in the final model.
The final CD4 model was adjusted for baseline viral load
and race. Neither age, presence of genital infections, nor the
spline terms for baseline viral load were retained in the final
model since their removal changed the HSV-2 coefficient
estimate by less than 10%. The interaction term between
HSV-2 and time was statistically significant (P ¼ 0.006),
indicating that HSV-2-seropositive women, compared with
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HSV-2-seronegative women, had an increase of 8 cells/mm3
per year over the study period. This result, while statistically
significant, was in the opposite direction from that expected
and is likely not clinically meaningful because of the small
change in CD4 count over time. As in the viral load model,
we assessed whether the effect of HSV-2 on CD4 over time
was nonlinear by including an interaction term between
HSV and the polynomial term for time. The likelihood ratio
test comparing the model without the interaction term with
the model with it was nonsignificant (P ¼ 0.32), so the term
was not retained in the final model.
HSV-2 therefore did not notably influence the trajectories
of HIV viral load and CD4 counts over time. The mean
predicted HIV plasma viral load values and CD4 counts
from the mixed models are shown graphically in Figure
1A and 1B, respectively, stratified by HSV-2 serostatus.
The graphs presented are the predicted lines for those in-
dividuals in the referent group of each category (median
baseline viral load, median CD4 count, absence of genital
infections, and nonblack race). Plots for other groups looked
similar but are not shown.
When data were restricted to the 57.5% of study visits
where women reported no current use of antiretrovirals, re-
sults from the viral load model were similar. In the CD4
model, the interaction between HSV and time was smaller
(HSV-2-seropositive women, compared with HSV-2-
seronegative women, had an increase in CD4 of 3 cells/
mm3 per year over the study period) and was nonsignificant
(P ¼ 0.45). When study visits where women reported cur-
rent use of the antivirals Cytovene (n ¼ 12 visits), Foscavir
Table 1. Baseline Characteristics of 777 HIV-Positive USWomen From the HIV Epidemiology Research Study (1993–2000), Stratified by HSV-2
Serostatus
Characteristic
HSV-2 Seropositive (N 5 527)a HSV-2 Seronegative (N 5 250)a
P Valueb
No. % Median Range No. % Median Range
Baseline viral load, log copies/mL 3.1 1.4–5.7 3.2 1.4–5.3 0.44
Baseline CD4 count, cells/100 362 6–1,684 412 4–1,577 0.06
Age, years 36 19–55 34 19–53 0.0009
Age at first intercourse, years 15 8–28 15 8–27 0.65
Race 0.0003
Black 347 65.8 131 52.4
Nonblack 180 34.2 119 47.6
Marital status 0.92
Married/cohabiting 139 26.7 72 28.9
Separated/divorced 108 20.8 50 20.1
Single 224 43.1 106 42.6
Widowed 48 9.2 21 8.4
Current smoker 397 75.3 189 75.6 0.94
Condom use in the last 6 months 0.55
No vaginal sex in the last 6 months 136 26.1 58 23.3
Always used a condom 202 38.7 106 42.6
Did not always use a condom 184 35.2 85 34.1
No. of male sexual partners in the
last 6 months
1 1–99 1 1–25 0.22
Sexually transmitted infections
HSV-1 seropositive 375 71.2 201 80.4 0.006
Chlamydia culture positive 3 0.9 3 1.46 0.68c
Gonorrhea culture positive 2 0.4 3 1.3 0.34c
Syphilis seropositive 53 10.2 12 4.9 0.015
Trichomonas culture or wet
mount positive
79 15.1 26 10.4 0.081
Candida culture positive 205 39.6 86 34.7 0.19
Abbreviations: HIV, human immunodeficiency virus; HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2.
a Frequencies do not always add to the total number because of missing values.
b P values were calculated using the Wilcoxon rank sum test for continuous variables and the v2 statistic for categorical variables, unless noted
otherwise.
c P values were calculated using Fisher’s exact test because of small cell sizes.
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(n ¼ 328 visits), and amantadine (n ¼ 2 visits) were
excluded, results were similar for both the viral load and
CD4 models.
These results were consistent with the Kaplan-Meier
curves examining the time to AIDS diagnosis by baseline
HSV-2 serostatus (data not shown). The hazard ratio com-
paring HSV-2-seropositive women with those who were
HSV-2 seronegative at baseline was 0.99 (95% confidence
interval: 0.77, 1.23).
DISCUSSION
These data from the HERS study do not support a clini-
cally meaningful effect of baseline HSV-2 seropositivity on
the trajectories of HIV plasma viral loads or CD4 counts
among 777 HIV-seropositive women. By censoring the data
at January 1, 1998, and removing most visits where women
were receiving HAART, we examined the effect of HSV-2
seropositivity on the natural history of HIV.
Our results are fairly consistent with those of several
smaller studies examining the effect of HSV-2 on viral load
and CD4. For instance, in a longitudinal cohort study in
San Diego, California (15), and a cross-sectional study in
Rakai, Uganda (9), no differences in HIV plasma viral load
were observed between HSV-2-seropositive and HSV-2-
seronegative men and women with prevalent HIV infection.
In the San Diego study, the median HIV viral load was 5.04
log10 copies/mL (range: 1.70–7.24) among 172 HSV-2-
seronegative individuals compared with a median HIV viral
load of 4.87 log10 copies/mL (range: 1.70–7.76) among 122
HSV-2-seropositive individuals (15). Among 115 HSV-2-
seronegative individuals with HIV infection in the Rakai
study, the mean HIV plasma RNA viral load was 4.18
log10 copies/mL (standard deviation, 0.83) compared with
a mean HIV plasma RNA viral load of 4.09 log10 copies/mL
(standard deviation, 0.84) among 230 HSV-2-seropositive
individuals (9).
In contrast to our results, a 2005 observational study of 339
individuals with prevalent HIV infection not receiving acy-
clovir or HAART in Uganda found that HSV-2 coinfection
was associated with a 0.3-log10-copies/mL higher mean HIV
viral load (4.6 (standard deviation, 0.94) vs. 4.3 (standard
deviation, 0.91) log copies/mL, P ¼ 0.014) (10). While the
effect of HSV-2 on CD4 count over time was statistically
significant in our study, it is likely not clinically meaningful.
The lack of a strong association between HSV-2 seropositiv-
ity and CD4 counts is supported by the Ugandan study, where
no change in CD4 count over time was observed between
HSV-2-seropositive and HSV-2-seronegative individuals.
It is plausible that HSV-2 infection is associated with in-
creased HIV RNA plasma viral load, given data from lon-
gitudinal studies of HSV-2 suppression that demonstrate an
effect of acyclovir on reducing HIV RNA plasma viral load
(21). Most of our study population was acyclovir-naı̈ve;
therefore, we could not examine this association directly.
One possibility for the lack of an association between
HSV-2 seropositivity and HIV viral load in our study and
the presence of an association in HSV-2 suppression studies
is that acyclovir acts directly on HIV RNA rather than
through HSV-2 suppression. A recent study found that acy-
clovir suppresses HIV in human herpesvirus-coinfected hu-
man tissues. Once acyclovir is phosphorylated by human
herpesvirus kinases, it can directly inhibit HIV reverse tran-
scriptase (22). These data suggest that acyclovir’s anti-HIV
activity in the presence of HSV may contribute to the re-
sponse of acyclovir in HIV/HSV–coinfected patients.
In terms of study strengths, HERS is one of the largest
longitudinal studies of women with or at risk of HIV in-
fection. With its 7 years of follow-up and high retention
rate, it represents one of the largest studies to date to analyze
Table 2. Summary of Estimated Regression Coefficients From Final Mixed Models for
Associations Between Baseline HSV-2 Seropositivity and 1) HIV Viral Load and 2) CD4 Count/
100 Over Study Follow-up, HIV Epidemiology Research Study, United States, 1993–2000
Variable
HIV Log Viral Load Model CD4 Count/100 Model
b̂a SE P Value b̂a SE P Value
Intercept 2.80 0.12 <0.0001 3.95 0.47 <0.0001
HSV-2 0.02 0.06 0.75 0.18 0.17 0.28
Time since baseline 0.38 0.03 <0.0001 0.68 0.05 <0.0001
HSV-2 3 time since
baseline
0.02 0.02 0.23 0.08 0.03 0.006
Time since baseline
squared
0.10 0.01 <0.0001 0.09 0.01 <0.0001
Baseline CD4 count/100b 0.34 0.05 <0.0001
Baseline viral load (log10)
b 1.91 0.39 <0.0001




Abbreviations: HIV, human immunodeficiency virus; HSV-2, herpes simplex virus type 2; SE,
estimated standard error.
a Estimated regression coefficients from the final mixed model.
b Variable is centered at the median.
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Figure 1. Mean predicted values from the mixed model by herpes simplex virus type 2 (HSV-2) status with individual visit data for A) human
immunodeficiency virus (HIV) viral load (log copies/mL) and B) CD4 counts (cells/100), United States, 1993–2000. Solid line: HSV-2 seronegative
at baseline; dashed line: HSV-2 seropositive at baseline; open circle: CD4 or HIV viral load for a woman HSV-2 seronegative at baseline;þ: CD4 or
HIV viral load for a woman HSV-2 seropositive at baseline. Horizontal line at viral load ¼ 1.7 log copies/mL indicates the limit of detection. Refer to
the Materials and Methods section of the text for more information about the HIV viral load and CD4 models. The graphs are the predicted lines for
those women in the referent group of each category (median baseline viral load or median baseline CD4 count, absence of genital infections, and
nonblack race). Data were jittered before time 0 in both graphs and around the viral load limit of detection in the viral load graph.
842 Hoots et al.
Am J Epidemiol. 2011;173(7):837–844
the effect of HSV-2 serostatus on HIV plasma viral load and
CD4 counts. One study limitation is that HSV-2 serostatus
was measured at baseline only. If women contracted HSV-2
over the 7 years of follow-up, they would subsequently be
misclassified as HSV-2 seronegative in analyses. This non-
differential misclassification of the exposure could result in
biasing the effect of HSV-2 on HIV plasma viral load or CD4
counts over time toward the null in expectation under a mono-
tonicity assumption. A previous study of HSV-2 seroconver-
sion among 850 HIV-infected individuals in London, United
Kingdom, demonstrated an HSV-2 seroincidence of 1.8 per
100 person-years. If seroconversion was similarly low in
this study, our results were likely not greatly biased by this
limitation (23).
HSV-2 serostatus could also have been misclassified if
HSV-2 seropositivity was the result of oral HSV-2 infection
in some women. Although oral HSV-2 infection exposure is
possible, HSV-2 seropositivity is generally considered in-
dicative of past exposure to genital herpes, because most
women with oral HSV-2 infection have also been exposed
genitally (24). In addition, because HSV-2 was measured at
baseline only, the mixed-model analysis conducted did not
enable estimation of total causal effects. We also did not
include HAART use as a potential confounder in the models
because it was time varying and was measured after the
baseline exposure. While censoring the data on January 1,
1998, removed a large number of study visits where women
were receiving HAART, confounding due to use of sub-
HAART therapies was likely still present. To address this
problem, we conducted a sensitivity analysis in which we fit
the models to only those person-visits where women re-
ported no current use of antiretrovirals; results were similar,
albeit less precise. Future longitudinal research should test
for HSV-2 serostatus at each study visit and use marginal
structural modeling to assess the total causal effect of HSV-
2 on the trajectories of HIV viral load and CD4 counts,
adjusting for HAART use.
Another limitation of the study is that data on HSV-2
shedding from the genital tract and frequency of outbreaks
of genital lesions were not available. We were therefore
unable to determine whether transient increases in plasma
HIV viral load occurred during periods of HSV-2 shedding
or outbreaks. Furthermore, data on recency of HIV infection
were not available to examine whether HIV viral load dif-
fered by HSV-2 serostatus for women with recent HIV
infections.
Although HSV-2 and HIV-1 infections tend to be coprev-
alent, these data suggest that HSV-2 serostatus does not
affect the trajectories of HIV plasma viral loads or CD4
counts. Further prospective studies are needed to examine
the effect of HSV-2 acquisition and reactivation on HIV
dynamics to determine whether HSV-2 can potentially affect
the viral set point of HIV.
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